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Hawaii State Department of Health epidemiological 
records were reviewed for cases of ciguatera poisoning for 
the entire state ,from January 1984 through December 1988. 
During the 5 year interval, the numbers of ciguatera poison-
ing incidents, number of cases, and date of onset were record-
ed, as well as age and sex of individuals involved. The place 
of catch of each fish was noted as well as whether or not the 
fish was obtained commercially. The parts of the fish con-
sumed were also recorded. 
A total of 150 ciguatera incidents occurred during this 
period, involving 462 individuals for an average annual inci-
dence rate of 8.71100,000 population. The 3 most frequently 
implicated species of fish were the Carangoides species (jack 
or papio or ulua), Ctenochaetus strigosus (surgeon fish or 
kole), and Aphareus furcatus (fork-tailed snapper or waha 
nui); however, more than 50 species offish had caused one or 
more outbreaks. The most frequently implicated areas of the 
toxic fish were the Kona coast as well as the South Point of 
the island of Hawaii, and the Napali coast of the island of 
Kauai. Of the 150 outbreaks, 32 (21%) were related to com-
mercial fish. The rest were related to sportfishing. 
Introduction and history 
Ciguatera fish poisoning is a disease which results from the 
ingestion of reef fish. For many years it was primarily a con-
cern of those residing in the tropics or subtropics. However, it 
is becoming increasingly significant for fish-eaters in temper-
ate areas of the world as well, as fish has become more popu-
lar and quick air delivery of fresh fish is a reality'·6• Ciguatera 
fish poisoning is generally thought to be caused by a polyether 
toxin, usually ciguatoxin (CTX). It is likely however, that the 
symptom complex we describe as ciguatera, may actually be a 
result of the consumption of other polyether toxins, such as 
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... every once in awhile 
palytoxin, scaritoxin, maitotoxin and other as of yet unidenti-
fied toxins7• 
Ciguatera is not a new disease. The term was coined during 
the 18th century, when it was noted that a symptom complex 
would sometimes develop following the ingestion of a marine 
snail, Turbo pica, also commonly known as "cigua"'5• There 
were reports of illness due to the consumption of fish noted by 
the Egyptians during ancient times'2• There is also evidence to 
suggest that there were cases of ciguatera poisoning during the 
voyages of Captain Bligh and Captain James Cook'6•17 • 
The illness has been extending to new areas however, partly 
due to modern transportation, that allows fresh fish to be sold 
in inland areas, and also because of ecological changes that 
may be contributing to ciguatera endemicity in certain areas of 
the Pacific. The mechanism of these ecological changes is not 
well elucidated at this point, but it has been frequently noted 
that ciguatoxic fish will often increase, or suddenly appear in 
previously unaffected areas, following an upset in the benthic 
environment, as may occur during coastal construction projects 
or dredging, or underwater nuclear bomb testing13•18• 
The primary endemic areas, however, are still the tropical 
and subtropical coastal regions of the world, particularly in 
the South Pacific islands and the Caribbean19.2°. In the United 
States, most cases occur in Hawaii and in Southeastern 
Florida, although cases have been reported from Texas, 
California and occasionally the inland states as the result of 
importing fish from endemic areas1·6•12•13•21 • 
Pathogenesis 
It has been determined that ciguatoxin is produced by a 
photosynthetic benthic dinoflagellate Gambierdiscus toxicus, 
which lives in the coral reef environment8• Herbivorous fish 
consume the organism in algae that contain the toxin and con-
centrate the CTX in their internal organs and flesh. These fish 
may then be consumed by larger carnivorous fish, which in 
turn concentrate the toxin to a greater extent. Thus, the toxin 
passes up the food chain to the human consumer. The pres-
ence of toxic fish tends to be sporadic and unpredictable, mak-
ing it impossible without the use of scientific testing to deter-
mine whether or not a fish caught from a specific area, at a 
specific time, may be safe to eat. 
Individual susceptibility to the toxin varies considerably. A 
given amount of fish, when consumed by one person may 
cause illness, whereas another person may remain well. It has 
been demonstrated that susceptibility to the toxin may 
increase after a previous exposure, and people who have suf-
fered from ciguatera in the past may actually become more 
susceptible to the disease9•10• Even in the absence of symptoms 
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at ftrst exposure, those with frequent intake of ciguatoxic ftsh 
are more likely to become ill. This may be a matter of accu-
mulation of CTX in the host, or possibly an immunologic 
reaction. 
It is interesting to note that individuals suffering from 
ciguatera will often have symptoms after eating any seafood, 
and often nuts, nut oils and alcoholic beverages as well. The 
mechanism behind this phenomenon is as yet unknown, but it 
is recommended that individuals suffering from ciguatera fol-
low a diet avoiding such products11 • 
The toxin involved in ciguatera is odorless and tasteless. 
There is no ordinary means of detecting the presence of the 
toxin other than by scientific testing. The toxin is heat-stable, 
and is not destroyed by boiling, steaming, baking, smoking, 
salting, pickling or freezingt2.1l.t4• 
The mechanism whereby the polyether toxins affect a 
human has not yet been elucidated. Originally it was thought 
to exert its effect by an anticholinesterase activity, but later it 
was found to have a more complex mechanism of action 
which has yet to be determined22• 
Clinical manifestations 
The toxin primarily affects the gastrointestinal tract and the 
nervous system. Within about 4 to 10 hours after ingestion of a 
toxic ftsh, the individual typically develops gastrointestinal 
symptoms: Nausea, vomiting, diarrhea and abdominal cramps, 
often associated with a feeling of profound weakness and dys-
phoria. Muscle aches, joint pains, diaphoresis and chills may be 
present at this time as well. The gastrointestinal symptoms 
resolve after the first 12 hours of the illness 1 0 • 1 2. 13• 1 ~.20.2 l . 
Typically it is the neurologic symptoms that cause the pro-
longed discomfort in the disease. These neurologic symptoms 
generally begin at about the time the gastrointestinal com-
plaints are resolving, and consist of dysesthesias and paresthe-
sias particularly involving the perioral region and the distal 
extremities. Classically, one may experience the "temperature 
reversal phenomenon" whereas cold objects give a warm sen-
sation and touching warm objects results in a cold sensation. 
Often on drinking cold beverages, the person will describe a 
feeling of tingling of the tongue; cold beverages may feel hot, 
and vice-versa. The feeling of paresthesias is usually quite dis-
tressing; it may be described by some as a painful burning 
sensation. Pruritus typically develops as well, about one day 
after the onset of the initial gastrointestinal complaints. 
Symptoms usually last about one week, although may persist 
for months and be exacerbated by the consumption of other 
food products, as described above. 
Ciguatera is generally a self-limiting disease, but death 
may occur as a result of cardiac dysrhythmias, hypotension, 
shock or cerebral edema. The case-fatality rate varies from 
0.1% to 1%, depending on the geographic location'· 11 •12•1' . 
Treatment 
There is no speciftc treatment nor antidote for ciguatera. 
Treatment is generally symptomatic and consists of the 
administration of analgesics and specific drugs to treat the 
complications described above, should they develop. 
Mannitol, a commonly used diuretic, has been shown to 
WHEN EXPERIENCE COUNTS, 
COUNT ON HAWAIIAN TAX-FREE TRUST. 
92 
Ye , Hawaiian Tax- ree Tru l i an in e trn nt you 
can count on. A th first and large t fund in the l lands 
in e ting in muni ipal bonds the Trust ffers one of the 
few remaining way t earn tax-free in m together with 
a high I el of afety. 
M re ver, are ident of Hawaii 
y ur in orne fr m th Tru t i. free of botlr 
Federal and tate f Hawaii in orne taxe . * 
Be ·t of al l you get experienced. 
locall -b ed in tment management by 
----------------~ Aquila Distributors, Inc. I 
820 Mililani Stteet. Suite 400, Honolulu. Hawaii 96813 I 
YES, tell me more ;~bout how 1 an urn high monthly Income and pay 
no Federal and State ii'Kome t xes with the H Wil n Ti JC.frfl! Trurt. Please 
send a free prospectus contain ng more complete information. including all 
fees and eJCpense. I will rl!ad lt carefully before llmmt or send money 
PINse print dearly 
Name: _____ ____ ________ _ 
A~~------------------
Hawaiian ru t o. Ltd.- pe pie y u kn and can 
count on. 
You'll al . o njoy: 
a high-grad , wid ly di ifi d portfolio 
m nthly di id nd ** b ch k, 
r reinv ted ~ r y u without ale 
harg 
ready liquidity*• 
high current return 
lo initial in e tmenl - 1,000 
Make an investment that you and Hawaii can 
count on. For details, talk to your broker. Or call the 
Trust toll-free today. 
1-800-228-4227 
HAWAIIAN 
TAX·FREE TRUST 
City:. ________ State: __ Zlp: ___ __ 
I 
I 
I 
I 
I 
I 
I 
' 
1ndenomc ' rwmq , I unaJI pmlort of ill~Xl~M 11\1)' buubjcrl Ia.\ 01' CGtiUI 
Home~oo~ ( _____ ------------------------ ln\t:ilnn. • • han: .. Jue lllld divtdcnd 1111 llrC: not fiud md VII)' "i th ~rate fluctlll-nooo. Redc:mptimJ an: 11 the C\lrmllnd oo vAl"" ~Vbicn 111llf t..ll11ft or I tlwl am. 
BU1iness Phone: ( __ ) HMJ c 1992 IJi lrthulr!tl. l • 
HAWAII MEDICAL JoURNAL- VoL.51, No. 4-APRIL 1992 
FIGURE 1: 
ANNUAL INCIDENCE OF CIGUATERA 
STATE OF HAWAII, 1975 • 1988 
120 ~------------------------------~ 
100 
80 
60 
40 
__,._ NUMBER OF INCIDENTS --4- NUMBER OF CASES 
SOURCE: HAWAII STATE DEPARTMENT OF HEALTH 
FIGURE 2: 
CIGUATERA INCIDENTS 
ISLAND OF HAWAII, 1984 • 1988 
60 ,---------------------------------, 
1984 1985 1986 1987 
- INCIDENTS R NUMBER OF CASES 
SOURCE: HAWAII STATE DEPARTMENT OF HEALTH 
reduce remarkably the intensity and duration of symptoms of 
ciguatera in a number of patients23• As of yet, formal clinical 
trials using the drug have not been done; the mechanism of 
action of mannitol is unknown. It may be consequent to diure-
sis with subsequent rehydration that flushes out the ciguatox-
in. It may be a matter of the effects of mannitol on the sodium 
and potassium channels in the cell membrane. Less likely is 
the possibility of some type of direct chemical detoxification 
by the action of mannitol. 
It is also recommended that the patient suffering from 
ciguatera be placed on a "ciguatera diet" which involves 
avoidance of all seafood (even including those which are not 
usually contaminated with ciguatoxin, such as shellfish), as 
well as nuts, nut oils, sesame oil and alcoholic beverages until 
symptoms have completely subsided, in order to prevent the 
worsening or prolonging of symptoms11 • 
Epidemiology 
Epidemiological studies have been carried out in the South 
Pacific and Caribbean ocean areas in order to determine the 
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YEAR 
OAHU 
1984 
1985 
1986 
1987 
1988 
KAUAI 
1984 
1985 
1986 
1987 
1988 
MAUl 
1984 
1985 
1986 
1987 
1988 
HAWAII 
1984 
1985 
1986 
1987 
1988 
STATE 
1984 
1985 
1986 
1987 
1988 
TABLE 1: 
ANNUAL INCIDENCE OF CIGUATERA 
PER 100,000 POPULATION 
BY ISLAND AND YEAR: 1984 • 1988 
POPULATION 
802,351 
812,784 
818,487 
830,597 
838,194 est. 
44,167 
44,679 
46,440 
47,600 
47,700 est. 
74,750 
76,462 
78,790 
81,100 
90,300 est. 
107,169 
108,910 
112,039 
114,434 
115,200 est. 
1,037,206 
1,051,481 
1,064,732 
1,082,500 
1 ,091 ,394 est. 
ANNUAL INCIDENCE 
NO. CASES PER 100,000 POPULATION 
38 
29 
13 
40 
27 
17 
47 
8 
12 
6 
5 
5 
0 
11 
10 
26 
33 
53 
43 
39 
86 
114 
74 
106 
83 
4.7 
3.6 
1.6 
4.8 
3.2 
38.5 
105.0 
17.2 
25.2 
12.5 
6.7 
6.5 
0 
13.6 
11.1 
25.2 
30.3 
47.3 
37.6 
33.9 
8.3 
10.8 
7.0 
9.8 
7.5 
TOTAL 462 AVERAGE 8.7 
incidence in these endemic areas. Annual incidence rates var-
ied during the interval 1979 to 1983 from one case per 
100,000 people in the Solomon Islands to 1,338 per 100,000 
people in Tokelau19. Other high incidence areas with rates cal-
culated for the same interval were: French Polynesia with 585 
cases per 100,000; Kiribati, with 462 cases per 100,000; and 
Tuvalu, 484 cases per 100,00019. During the years 1982 to 
1987 the Marshall Islands had 234.9 cases per 1000 popula-
tion18. A study from St. Thomas, U.S. Virgin Islands, revealed 
an incidence rate of 36.5 cases per 1,000 population in 5 
years9. 
In the Virgin Islands, the most commonly implicated species 
of fish was the Caranx ruber (Carrang). In the South Pacific, in 
addition to the Carangidae (Jacks), Lycodontis javanicus 
(Moray eel) and Lutjanidae (snappers) were also highly suspect 
as the source of ciguatera25• In Fiji, the most commonly impli-
cated species was Sphyraena barracuda (Barracuda)l<. 
A previous epidemiologic investigation of ciguatera in the 
(Continued) >-
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Hawaiian Islands from 1975 to 1981 revealed an average inci-
dence rate of 1.3/100,000 population. Again, the Carangoides 
species (Jacks or Ulua and Papio) was the most frequently 
implicated, followed by Seriola dumerilii (Amberjack or 
Kahala), and Cheilinus rlwdochrous (Wrasse or Po'ou). Other 
implicated fish included the Mulloidichtys samoensis (Goat-
fish or Weke), Scaridae species (Parrotfish or Uhu), Mugil 
cephalus (Mullet or Amaama), Epinephelus guernus (Grouper 
or Hapuupuu) and Acanthurus dussumieri (Surgeonfish or 
Palani)13• 
The Hawaii State Department of Health (DoH) investigates 
each suspected case of ciguatera that is reported. Every ciguat-
era investigation involves an environmental, epidemiological 
and laboratory examination. The epidemiological investiga-
tion consists of determining the basic demographics of the 
cases: The timing and location of the outbreak; determining 
the parts of the fish eaten; the extent of symptoms; whether 
hospitalized; the number of work days missed and the dura-
tion of illness. This information is usually obtained by inter-
viewing the patients and often their physicians as well. 
The laboratory investigation includes the collection of any 
leftover fish samples and testing them with an ELISA test to 
determine semi-quantitatively the amount of polyether toxin 
present in the fish. This is done by a stick-test developed at 
the University of Hawaii26• 
The environmental investigation involves determining the 
place where the fish was caught or purchased; often means 
making a site-visit to the market or restaurant where the fish 
was obtained Companion samples of fish from the same catch 
may also have to be tested. The merchant is advised not to sell 
any fish of the same species from the same catch, nor remain-
ing parts of the same fish. The place of catch and the species 
of the fish is recorded (if available) and the involved mer-
chants are given information about ciguatera and other types 
of fish poisoning. 
Materials and methods 
DoH records of all reported ciguatera incidents were 
reviewed for the 5-year period 1984 to 1988. All probable or 
confirmed incidents were included in the investigation. Cases 
that occurred as the result of eating fish that were caught out-
side of the State were included. 
A "probable" case was defined as "experiencing both gas-
trointestinal and paraesthetic symptoms within 30 hours fol-
lowing the consumption of a fish implicated in ciguatera". A 
confrrmed case was defined as "a person with signs and symp-
toms compatible with ciguatera plus a positive poke-stick test 
of leftover fish eaten by that person." The term "incident" was 
used as opposed to "outbreak"; an outbreak generally refers to 
more than one person being ill, whereas an incident may refer 
to a single case. A person epidemiologically linked to an inci-
dent with a confrrmed case and exhibiting at least some com-
ponents of the gastrointestinal or neurological symptoms also 
was considered as a confirmed case. Information extracted 
from each chart included: The date of onset and location of the 
incident; the age and sex of the victims; the species of fish 
eaten; the place where the fiSh was obtained; and the parts of 
the fish consumed. 
The species of fish involved was usually identified by a 
common or Hawaiian name by those who saw the fish before 
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it was consumed. Occasionally fish markets had to be consult-
ed regarding the correct nomenclature, and in only one 
instance was the type of fish unknown. 
Several incidents occurred after the consumption of more 
than one type of fish. In these cases, the names of all the fish 
that may have been involved were recorded. The stick-test 
results of the fish were recorded as positive, borderline or neg-
ative, and were designated as either from the fish eaten or a 
companion sample (fish of the same species, caught at the 
same time and same location as the original fish). 
In order to help determine if there were unreported cases, 
emergency room records in 6 different hospitals throughout the 
State were reviewed in order to find cases with the diagnosis of 
ciguatera. None was found. The hospitals chosen were those 
whose record-keeping systems allowed such investigations to 
be performed. The information was stored and analyzed using 
the D-Base III plus program on a Wang PC-compatible com-
puter at the DoH office. Graphs were produced by Harvard 
Graphics. 
Results 
A total of 150 incidents were reported during the years 
1984 to 1988 in the State of Hawaii. These incidents occurred 
in all 4 counties of the State and were investigated by the DoH 
Epidemiology branch. The150 incidents (57 confirmed, 93 
probable) involved 462 cases of ciguatera. There were 652 
exposed individuals; the 462 cases, therefore, comprised an 
overall attack rate of 70.9%. However the attack rate varied 
greatly in each outbreak; some outbreaks had attack rates of 
100%. The island of Hawaii reported the most incidents, fol-
lowed by Oahu, Kauai and Maui respectively (Table 1). 
Although a significant increase in cases and incidents had 
been noted during the late 1970s and early 1980s, such increas-
es have not been noted for the 1984 to 1988 period (see Figure 
1). The island of Hawaii reported 8, 12, 12, 13, and 14 ciguat-
era incidents during each of the years from 1984 through 1988 
(Figure 2). The other islands did not show significant increases 
during the same 5-year period (Figures 3, 4 and 5). 
Kauai had 105 cases/100,000 population in 1985 primarily 
due to a problem with toxic Ctenochaetus strigosus (kole) fish 
HAWAII MEDICAL JOURNAL-VOL. 51, No. 4-APRIL 1992 
TABLE 2: 
INCIDENTS OF CIGUATERA BY SPECIES OF FISH 
IMPLICATED, STATE OF HAWAII: 1984 ·1988 
NAME OF FISH 
Ulua 
Papio 
Kola 
Wahanui 
Roi 
Po'ou 
Wake 
Barracuda 
Eel 
Kahala 
Pal ani 
Uku 
Ta'ape 
Mullet 
Opakapaka 
Omilu 
Moan a 
NUMBER OF INCIDENTS 
19 
16 
15 
12 
7 
6 
4 
4 
3 
3 
3 
3 
3 
3 
2 
2 
2 
Fish may be implicated more than once. 
TABLE 3: 
INCIDENCE OF CIGUATERA BY 
AREA CAUGHT AND ISLAND: 1984 ·1988 
AREA CAUGHT NO. OF INCIDENTS 
OAHU 
Reef Runway 3 
Kaena Point 3 
Barbers Point 2 
Haleiwa 2 
Waianae Coast 2 
Waianae 2 
HAWAII 
South Kona 7 
Milo Iii 7 
South Point 6 
Kawaihae 4 
Keei 4 
Puako 4 
Kona 2 
Punaluu 2 
MOLOKAI 2 
KAUAI 
Napali Coast 7 
Nualolo 2 
Fish may be implicated more than once. 
(Continued on page 97) )>-
95 
ONLY ONE HrANTAGONIST HEALS REFLUX ESOPHAGITIS 
AT DUODENAL ULCER DOSAGE. ONLY ONE. 
Of all the H2-receptor antagonists, only Axid heals and 4 .,.D® 
relieves reflux esophagitis at its standard duodenal ulcer dosage. ,...,.. • ~ 
Axid, 150 mg b.i.d., relieves heartburn in 86% of patients nizatidine 
after one day and 93% after one week. 1 150 b · d mg .1. . 
ACID TESTID. PADENT PROVEN. 
1. Data on file, Lilly Research Laboratories. See accompanying page for prescnbing information. 01991, Eu LILLY AND COMPANY NZ-2947-B-249304 
AXID® 
nizatidine capsules 
Brtef Summary. Consun the package Insert for 
complete prescribing Information. 
Indications and Usage: 1. Active duodenal ulcer-
for up to 8 weeks of treatment at a dosage of 300 mg 
h.s. or 150 mg b.i.d. Most patients heal within 4 weeks. 
2. Maintenance therapy- for healed duodenal ulcer 
patients at a dosage of 150 mg h.s. at bedtime. The 
coosequences of therapy with Axid for longer than 1 
year are not known. 
3. Gastroesophageal reffux disease (GERD)-for up 
to 12 weeks of treatment of endoscopically diagnosed 
esophagitis. iocluding erosive and ulcerative esophagitis. 
and associated heartburn at a dosage of 150 mg b.i.d. 
Contraindication: Known hypersensitivity to the drug. 
Because cross sensitivity in this class of compour1ds has 
been observed. H,-reoeptor antagonists, iocluding Axid, 
should not be administered to patients with a history 
of hypersensitivity to other H2-reoeptor antagonists. 
Precautions: General-f. Symptomatic response to nizatrdine therapy does not preclude the presence 
of gastric malignancy. 
2. Dosage should be reduced in patients with moderate to severe renal insufficiency. 
3. In patients with normal renal function and uncomplicated hepatic dysfunctioo, the disposition of 
nizatidlne is similar to that in normal subjects. 
Laboratory Tests-False-pos.tive tests iur urobilinogen with Multistix' may occur during therapy. 
Drug Interactions-No interactions have been observed with theophylline, chlordiazepoxide, lorazeparn, 
lidocaine, phenytoin, and warfarin. Axid does not inhibrt the cytochrome P-450 enzyme system; therefore, 
drug interactions mediated by inhibition of hepatic metabolism are not expected to occur. In patients given 
very high doses (3,900 mg) of aspirin daily, increased serum salicylate levels were seen when nizatidine, 
150 mg b.i.d., was administered coocurrently. 
Carcinogenesis, Mutagenesis, lmpainment of Fertility-A 2-year oral carcinogenicity study in rats with 
doses as high as 500 mglkglday (abou160 times the recommended daily therapeutic dose) showed no evidence 
of a carcinogenic effect There was a dose-related increase in the density of enterochromaffin-like (ECL) cells 
in the gastric oxyntic mucosa In a 2-year study in mice, there was no evidence of a carcinogenic effeol in male 
mice, although hyperplastic nodules of the liver were increased in the high-dose males as compared with 
placebo. Female mice given the high dose of Axid (2,000 mglkglday, about 330 times the human dose) showed 
marginally ststistically significant increases in hepatic cardnoma and hepatic nodular hyperplasia with no 
numerical increase seen in any of the other dose groups. The rate of hepatic carcinoma in the high-dose 
animals was within the historical cootrol limits seen for the strain of mice used. The female mice were given 
a dose larger than the maximum tolerated dose, as indicated by excessive (30%) weight decrement as compared 
with coocurrenf cootrols and evdence of mild liver injury (transaminase alevations). The occurrence of a marginal 
finding at high dose ooly in animals given an excessive and wmewhat hepatotoxic dose, with no evdence of a 
carcinogenic effect in rats, male mice, and female mice (given up to 360 mglkglday, about 60 times the human 
dose), and a negative mutagenicity battery are not corsidered evdence of a carcinogenic potential for Axid. 
Axid was not mutagenic in a battery of tests pertormed to evaluate its potential genetic toxicity, including 
bacterial mutation tests, unscheduled DNA syntheaJs, sister chromatid exdhange, mouse lymphoma assay, 
chromosome aberration tests, and a micronucleus test 
In a 2-generation, perinatal and postriatal fertility study in rats, doses of nizatidine up to 650 mglkglday 
produced no adverse effects on the reproductive pertorrnance of parental animals or their progeny. 
Pregnancy- Teratogenic Effects-Pregnancy Category C-Oral reproduction studies in rats at doses up 
to 300 times the human dose and in Dutch Belted rabbrts at doses up to 55 times the human dose reveaed no 
evidence of impaired fertility or teratogenic effect; but, at a dose equivalent to 300 times the human dose, 
treated rabbits had albortioos, decreased number of live fetuses, and depressed fetal weights. On intravenous 
administratioo to pregnant New Zealand White rabbits, nizatidine at 20 mglkg produced cardiac enlargernen~ 
coarctation of the aortic arch, and cutaneous edema in 1 tetus, and at 50 mgll<g, rt produced ventricular 
anomaly, distended atrdomen, spina bifida, hydrocephaly, and enlarged heart in 1 fetus. The<e are, however, 
no adequate and well-cootrofled studies in pregnant wurnen. tt is alw not known wihether nizatrdine can 
cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nizatidine 
should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 
Nursing Mothers-Studies in lectating women have shown that 0.1% of an oral dose is secreted 
in human milk in proportioo to plasma concentrations. Because of growth depression in pups reared 
by treated lactating rats, a decision should be made wihether to discontinue nursing or the drug, takng 
into account the importance of the drug to the mother. 
Pediatric Use-Safety and effectiveness in children have not been established. 
Use in Bderfy Pauents- Healing rates in elderly patients were similar to those in younger age groups 
as were the rates of adverse events and latioratory test abnormalities. Age alone may not be an important 
factor in the disposition of nizattdine. Bdeny patients may have reduced renal function. 
Adverse Reactions: Worfdwice, cortrolled clinical trials included over 6,000 patients given nizatidine in 
studies of veryng durations. Placebo-ron trolled trials in the Unrted States and Canada included over 2,600 patients 
given nizatidine and over 1,700 given placetio. Among the adverse events in these placebo-cortrolled trials, only 
anemia (0.2% vs 0%) and urticaria (0.5% vs 0.1%) were significantly more common in the nizatidine group. Of 
the adverse events that occurred at a frequency of 1% or more, there was no statisticaly signif!Gaflt difference 
between Axid and placebo in the incidence of any of these events (see package insert for complete information). 
A variety of less common events were also reported; it was not possible to detenmine wihether these 
were caused by nizatidine. 
Hepauc-Hepatocellular injury (elevated liver enzyme tests or alkaline phosphatase) possibly or probably 
related to nizatidine occurred in some patients. In some cases, there was marked elevation (>500 lUll) in 
SGOT or SGPT and, in a single instance, SGPT was >2,000 lUlL. The incidence of elevated liver enzymes 
overall and elevations of up to 3 times the upper limit of normal, however, did not significantly differ from that 
in placebo patients. All abnormalities were reversible after discontinuation of Axid. Since market introduction, 
hepatitis and jaundice have been reported. Rare cases of cholestatic or mixed hepatocellular and cholestatic 
injury with jaundice have been reported with reversal of the atinomnalities after discontinuation of Axid. 
Candiovascular-ln clinical pharmacology studies, short episodes of asymptomatic ventricular tachycardia 
occurred in 2 individuals administered Axid and in 3 untreated subjects. 
CNS- Rare cases of reversible mental coofusion have been reported. 
Endocrine-Clinical pharmacology studies aAd cootrolled clinical trials showed no evidence of anti-
androgenic activity due to nizatidine. Impotence and decreased libido were reported with similar frequency 
by patients on nizatidine and those on placebo. Gynecomastia has been reported rarely. 
Hematologic-Anemia was reported significantlly more frequently in nizatidine than in placebo-treated 
patients. Fatal tflrurnbocytopenia was reported in a patient treated with nizatrdine and another H2-reoeptor 
antagonist This patient had previou~y experienced thrombocytopenia while taking other drugs. Rare cases 
of thrombocytopenic purpura have been reported. 
Integumental-Urticaria was reported significantly more frequently in nizatidine- than in placeb<>-treated 
patients. Rash and extoliative denmatitis were alw reported. 
Hypersensitivity-As with other H,-reoeptor antagooists, rare cases of anaphylaxis following nizatidine 
administration have been reported. Rare episodes of hypersensitivity reactioos (eg, bronchospasm, laryngeal 
edema, ras.h, and eos.nophilia) have been reported. 
Other-Hyperuricemia unassociated with gout or nephrolithiasis was reported. Eosinophilia, lever, and 
nausea related to nizatidine have been reported. 
Overdosage: Overdoses of Axid have been reported rarely. ff overdos.age occurs, activated charcoal, 
emesis, or lavage should be coosidered along with clinical monitoring and supportive therapy. The ability of 
hemodialysis to remove nizatrdille from the body has not been conclus.ively demonstirated; however, due to its 
large volume of distribution, nizatidine is not expected to be efficiently removed from the body by this method. 
PV 2093 AMP [101591] 
AddWonal infonma6on available tv the profession on request. 
Ell Lilly and Company 
Indianapolis, Indiana 
46285 
NZ -294 7 -B-249304 © 1991, EU ULLY AND COMPANY 
HAW All MEDICAL JOURNAL-VOL. 51, No. 4-APRn.. 1992 
CIGUATERA (Continuedfrompage 95) 
FIGURE7: 
CIGUATERA INCIDENTS 1984 ·1988 
KOAE 
'"" ~·~ 
~fl~ :: 
-~· ~, .. ~  
""" ~ '""" ~·ru *~ ~ ~· -
K.lUAI 
,. OAHU 
.... ~MAUl 
·> •• , 
HAWAIIAN ISLANDS ISLAND OF HAWA!! 
FIGURES: 
CIGUATERA INCIDENTS 1984-1988 
ISLAND OF KAUAI 
on the Napali coast. 
The sex differential was 182 male patients and 17 4 
females. An age distribution curve shows a peak in the early 
fourth decade of life (Figure 6). 
The most frequently impugned species of fish were the 
Papio and Ulua causing a total of 35 incidents (Table 2). Kole 
were implicated in 15 ciguatera incidents. The third most fre-
quently involved fish was the Wahanui (Aphareus furcatus or 
fork-tailed snapper) in 12 incidents. Other fish involved in 
more than one ciguatera incident included: Roi (Cephalo-
phi/us guttatus blue-spotted grouper); Po'ou; Weke; Barra-
cuda); eel; Kahala; Palani; Uku (Aprion virescens gray snap-
per); Ta'ape (Lutjanus kasmira blue-lined snapper); Mullet; 
Opak:apaka (Pristipomoides filamentosus snapper); Moana 
(Parupeneus multifasciatus goatfish); and Omilu (Caranx 
melampygus blue crevally). There were additional individual 
incidents involving consumption of more than one of the 
above fish at a time, or other fish whose common names were: 
Sea bass, shark, rainbow runner, blue-lined surgeonfish, 
(Continued) >-
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smoked mackerel from the Philippines (Tinapa Galongong), 
Wahoo, false mullet, Japanese barracuda, Achilles tang, black 
trigger, milkfish, convict tang, squirrel-fish, porgy and red 
snapper. Oddly, there was one outbreak attributable to the 
consumption of octopus and another to Aku. 
The Kona coast of the island of Hawaii was responsible for 
the most incidents (Table 3). These fish were primarily caught 
by sportfishing off the Napali Coast of Kauai, South Point of 
Hawaii, Kaena Point, Barber's Point, Pokai Bay and the 
Waianae coast of Oahu (Figures 7, 8, 9 and 10). In addition to 
the sites represented on the maps, there were 2 episodes of 
ciguatera attributable to fish caught off Molokai, and one off 
the island of Lanai. 
No marked seasonal variation was observed in ciguatera 
incidents, although there was a slight increase noted during 
the third quarter of the year (July through September), and a 
decrease during the fourth quarter (October through 
December) during the 5-year period studied (Figure 11). 
Of the 150 known ciguatera incidents, in 130, records were 
kept indicating the parts of the fish that were consumed. In 59, 
parts of the fish other than the flesh, such as the head, viscera 
and roe, or a soup made from these parts, were consumed by at 
least one of the individuals who became ill . 
Commercially sold fish accounted for 33 out of the 150 
ciguatera incidents (22%). These fish were either consumed in 
a restaurant or were purchased from markets. The other 78% 
of incidents were attributable to fish caught recreationally. 
In 89 incidents fish were available for testing using the 
stick-test, either leftovers of the fish actually eaten or fish 
from a companion catch. The putative fish itself was available 
for testing in only 61 incidents. 
Discussion 
The statewide incidence rate of 8.7/100,000 shows a signifi-
cant increase over the previous epidemiologic study of 1975 to 
1981 that demonstrated an incidence of 3/100,00013 • The 
increase occurred largely during the early 1980s (Figures 1 and 
2). (In referring to the figures, it is important for the reader to 
realize that the number of incidents correlates more closely with 
the actual endemicity of ciguatera at a given period of time 
rather than with the number of cases; the latter relates to the 
number of people who ate the toxic fish. Thus, a single out-
break affecting 100 people would be of less consequence epi-
demiologically than 100 different fish making 100 people ill.) 
This may be a result of increased awareness of the disease and 
better reporting, but it is also likely that there actually has been 
an increase in ciguatera in the Hawaiian Islands. This may be 
due to changes in the reef environment similar to what has 
occurred in the Marshall islands18• 
In the last 5 years, however, the ciguatera rates seem to have 
reached a plateau. The areas typically affected are the leeward 
coastal areas. Areas of dredging and construction will often 
show an increase in ciguatoxic fish, such as when the reef-run-
way at Honolulu International Airport was constructed. 
Construction lasted from May 1973 to December 1977. The 
first toxic fish began to be recorded in April, 1978, 4 months 
after the construction ceased, and toxic fish are still known to 
inhabit the region. The Pokai Bay area of the Waianae Coast 
underwent construction of a breakwater from April 1977 to 
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January 1979; it involved dredging, filling and blasting. After 
15 months, reports of toxic fish began appearing, and to the pre-
sent, the Pokai Bay area is known for its ciguatera problem '3• 
The large increase in reported cases from the Kona coast of the 
Big Island may also be related to the multiple construction pro-
jects that occurred earlier this decade. 
The age of onset of the disease correlates well with the ages 
of individuals more likely to be out fishing. If it is true that the 
susceptibility to ciguatoxin increases with repeated previous 
exposure, one would expect that older age groups with more 
years of exposure to ciguatoxin would have more cases of ill-
ness. Age distributions in other studies have been similar9.27• 
The slight increase in the number of ciguatera incidents 
during the third quarter of the year may be due to climatic 
changes of the reef environment, or an increase in fishing 
activity during that time of the year. The decrease during the 
fourth quarter may be due to cooler and increasingly rainy 
weather. A seasonal study from Puerto Rico showed definite 
seasonal trends with peak seasons for ciguatoxic barracuda 
occurring in January to May, and August to Novembers. 
In 59 of the 150 ciguatera incidents, at least one (and usually 
more) of the victims consumed a portion of the fish known to 
concentrate the ciguatoxin, notably the gut, liver, head and roe, 
as well as a soup or broth made of the latter. It is likely that 
many, if not most, of these outbreaks (a large proportion of the 
total) could have been avoided if the individuals involved had 
been educated regarding ciguatera and the concentration of the 
ciguatoxin in these parts of the fish. 
Ciguatera is of great concern at local fish markets, which 
attempt to avoid the sale of toxic fish by avoiding buying fish 
caught near leeward reefs, as well as avoiding the sale of spe-
cific species known to be toxic. The Kahala is an example of a 
fish that is no longer sold in local markets due to its high 
prevalence for ciguatoxicity. 
The use of the stick-test for commercial use does not appear 
to be cost-effective. It is reassuring to know that in the year 
1987, among a total of 164,910 reef fish caught commercially, 
only 5 incidents of ciguatera poisoning were reported, only 
. 003% of the total reef fish caught. The year 1987 is represen-
tative of other years as well, in which commercial ciguatoxic 
fish have only been implicated, ie in 3 to 10 incidents per year 
during the years 1984 to 1988. 
The major source of ciguatera cases has been the fish caught 
by sportfishing, typically on weekends and holidays. If people 
could be educated to avoid consuming heads, viscera and roe of 
reef fish (especially a soup made of the above); and avoid fish 
caught in the areas known for being ciguatera-prone, the rates 
of ciguatera would decrease dramatically. The addition of the 
stick-test for use in sportfishing could reduce the rates of illness 
even more. 
Since the future incidence of ciguatera is unpredictable, we 
cannot assume the problem will go away. We can, however, 
significantly reduce the probability of future outbreaks by 
educating the public, and by encouraging the use of the stick-
test in sportfishing. 
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